Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dendritic cell (DC)-based hepatitis B virus T epitope peptide

A hepatitis B virus and epitope peptide technology, applied in the fields of genetic engineering, biomedicine, and protein engineering, can solve problems such as inability to cure hepatitis B or other complications, and inability to effectively block liver fibrosis and sclerosis. The effect of blocking liver fibrosis and hardening and improving clinical symptoms

Inactive Publication Date: 2011-09-21
江苏安泰生物技术有限公司
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta transmits to the fetus and blocks the transmission of hepatitis B virus to breastfed newborns through milk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dendritic cell (DC)-based hepatitis B virus T epitope peptide
  • Dendritic cell (DC)-based hepatitis B virus T epitope peptide
  • Dendritic cell (DC)-based hepatitis B virus T epitope peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The DC cell-based hepatitis B virus T epitope peptide of the present invention has an amino acid sequence of QLFHLCLII and a molecular weight of 1150.

[0022] The epitope peptide was synthesized using the standard Fmoc protocol, and after purification by HPLC, its purity was greater than 98%, see figure 1 , mass spectrometry and confirmed its molecular weight in line with the theoretical value.

[0023] The synthesis method of the hepatitis B virus T epitope peptide based on DC cells of the present invention is:

[0024] 1. Design and screening of epitope peptides

[0025] 1. Hepatitis B virus antigen

[0026] 乙型病毒抗原的核心抗原为乙肝病毒在体内引起CTL反应的主要抗原,核苷酸序列为639bp,编码蛋白为212氨基酸, MQLFHLCLIISCSCPTVQASKLCLGWLWGMDIDPYKEFGASVELLSFLPSDFFPSIRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMNLAT W VGSNLEDPASRELVVSYVNVNMGLKIRQLLWFHISCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQ

[0027] 2. Homology analysis

[0028] Blast the 212 amino acids with the protein fragment in the NCBI ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of protein engineering, gene engineering and biomedicines, in particular to a dendritic cell (DC)-based hepatitis B virus T epitope peptide. The technical scheme is that: the DC-based hepatitis B virus T epitope peptide is characterized by consisting of nine amino acid residues in the amino acid sequence of QLFHLCLII. The basic amino acid is taken as a framework, same preset amino acid sequences are simultaneously synthesized on the framework by a solid-phase synthesis technology, a hepatitis B virus is taken as a design target, and the DC-based hepatitis B virus specific epitope peptide is produced by the synthesis technology; the DC is loaded with the epitope peptide in vitro, and the mature DC is injected into bodies of a specific group to specifically generate effects of removing in-vive virus and improving clinical symptoms aiming at hepatitis B virus infection, particularly chronic hepatitis.

Description

technical field [0001] The invention relates to the fields of protein engineering, genetic engineering and biomedicine, in particular to a DC cell-based hepatitis B virus T epitope peptide. Background technique [0002] Worldwide, more than 400 million people are infected with the hepatitis B virus, and 1 million people die each year from complications of the infection, including cirrhosis, hepatocellular carcinoma, or other complications. Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta is transmitted to the fetus, and the transmission of hepatitis B virus to breast-fed newborns through milk is blocked. [0003] Peptide synthesis technology is currently carried out in some institu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06A61P31/20A61P1/16
Inventor 罗进闫小君
Owner 江苏安泰生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com